about
(Secondary) solid tumors in thyroid cancer patients treated with the multi-kinase inhibitor sorafenib may present diagnostic challenges.Beneficial Effects of the mTOR Inhibitor Everolimus in Patients with Advanced Medullary Thyroid Carcinoma: Subgroup Results of a Phase II Trial.Loss of MAPK Pathway Activation in Post-Mitotic Retinal Cells as Mechanism in MEK Inhibition-Related Retinopathy in Cancer Patients.Everolimus pharmacokinetics and its exposure-toxicity relationship in patients with thyroid cancer.A Semi-Physiological Population Model to Quantify the Effect of Hematocrit on Everolimus Pharmacokinetics and Pharmacodynamics in Cancer Patients.Therapy of endocrine disease: response and toxicity of small-molecule tyrosine kinase inhibitors in patients with thyroid carcinoma: a systematic review and meta-analysis.Neoantigen landscape dynamics during human melanoma-T cell interactions.Dutch Melanoma Treatment Registry: Quality assurance in the care of patients with metastatic melanoma in the Netherlands.Serous Retinopathy Associated with Mitogen-Activated Protein Kinase Kinase Inhibition (Binimetinib) for Metastatic Cutaneous and Uveal Melanoma.Long-term Survival and Clinical Benefit from Adoptive T-cell Transfer in Stage IV Melanoma Patients Is Determined by a Four-Parameter Tumor Immune Signature.Anti-PD1 treatment in metastatic uveal melanoma in the Netherlands.Randomised study of tegafur-uracil plus leucovorin versus capecitabine as first-line therapy in elderly patients with advanced colorectal cancer--TLC study.Prospective Clinical and Pharmacological Evaluation of the Delcath System's Second-Generation (GEN2) Hemofiltration System in Patients Undergoing Percutaneous Hepatic Perfusion with MelphalanAnti-CTLA-4 therapy broadens the melanoma-reactive CD8+ T cell response.Erratum to: Prospective Clinical and Pharmacological Evaluation of the Delcath System's Second-Generation (GEN2) Hemofiltration System in Patients Undergoing Percutaneous Hepatic Perfusion with Melphalan.Feasibility and effectiveness of trifluridine/tipiracil in metastatic colorectal cancer: real-life data from The Netherlands.Isolated (hypoxic) hepatic perfusion with high-dose chemotherapy in patients with unresectable liver metastases of uveal melanoma: results from two experienced centres.Preoperative chemoradiation therapy in combination with panitumumab for patients with resectable esophageal cancer: the PACT study.Selumetinib in Combination With Dacarbazine in Patients With Metastatic Uveal Melanoma: A Phase III, Multicenter, Randomized Trial (SUMIT).Percutaneous Hepatic Perfusion (PHP) with Melphalan as a Treatment for Unresectable Metastases Confined to the Liver.To treat or not to treat: developments in the field of advanced differentiated thyroid cancer.Adjuvant chemotherapy for rectal cancer patients treated with preoperative (chemo)radiotherapy and total mesorectal excision: a Dutch Colorectal Cancer Group (DCCG) randomized phase III trialQuality of Life After Curative Resection for Rectal Cancer in Patients Treated With Adjuvant Chemotherapy Compared With Observation: Results of the Randomized Phase III SCRIPT TrialSafety of Percutaneous Hepatic Perfusion with Melphalan in Patients with Unresectable Liver Metastases from Ocular Melanoma Using the Delcath Systems' Second-Generation Hemofiltration System: A Prospective Non-randomized Phase II TrialEverolimus in Patients With Advanced Follicular-Derived Thyroid Cancer: Results of a Phase II Clinical TrialGenomic Profiling of Metastatic Uveal Melanoma and Clinical Results of a Phase I Study of the Protein Kinase C Inhibitor AEB071Treatment strategies and overall survival for incurable metastatic colorectal cancer - A EURECCA international comparison including 21,196 patients from the Netherlands and NorwayThe Drug Rediscovery protocol facilitates the expanded use of existing anticancer drugsThe impact of current treatment modalities on the outcomes of patients with melanoma brain metastases: A systematic reviewA unique case of two somatic APC mutations in an early onset cribriform-morular variant of papillary thyroid carcinoma and overview of the literatureMalignant pheochromocytoma and paraganglioma: management optionsLow-dose interferon-alpha preconditioning and adoptive cell therapy in patients with metastatic melanoma refractory to standard (immune) therapies: a phase I/II studyEmbolization of variant hepatic arteries in patients undergoing percutaneous hepatic perfusion for unresectable liver metastases from ocular melanomaTargetable gene fusions identified in radioactive iodine refractory advanced thyroid carcinomaEffectiveness and toxicity of lenvatinib in refractory thyroid cancer: Dutch real-life dataSwitching to Immune Checkpoint Inhibitors upon Response to Targeted Therapy; The Road to Long-Term Survival in Advanced Melanoma Patients with Highly Elevated Serum LDH?Efficacy and Adverse Events of Immunotherapy with Checkpoint Inhibitors in Older Patients with CancerMetastatic Uveal Melanoma: Treatment Strategies and Survival-Results from the Dutch Melanoma Treatment RegistrySo Close, yet so Far: Discrepancies between Uveal and Other Melanomas. A Position Paper from UM Cure 2020Phase Ib/II trial testing combined radiofrequency ablation and ipilimumab in uveal melanoma (SECIRA-UM)
P50
Q35898282-04E49D1A-8439-4913-B732-A61024116EDBQ35941777-48790351-7DDD-4056-8E9E-BB0D35C42F5FQ36891767-A5A68556-9280-4EF5-A4D8-E851055E1D67Q37038195-7E6A1E74-0E25-4041-9AF3-4102878DA775Q37348405-5388CB9A-6A82-40FF-A7DE-E3AAD30ADB13Q38311866-128AE080-2349-4AD9-837F-AC364708436FQ38761397-4FD8589C-2D58-4763-AFFF-F6961146B557Q38777179-04E7EC73-0777-4248-BE5F-60167B39ABAAQ40292507-0B66EA23-B5B1-440E-AE2D-382419C709D4Q40386814-29973F6E-D72B-4FC5-A072-BE1D82539FFDQ40444939-2973522A-5A0E-4ED4-B631-E7BF415E39A4Q40836685-D993DA68-66EB-4555-ACF0-BC53C27EEF7EQ41368436-8BE95F19-1DFD-4E94-A533-BD2EB3A42803Q42186944-1B5A0EEE-442C-41ED-9B28-027198D1B202Q47183068-090D9557-8BD8-45F6-ACD5-E0A34AFA9432Q47369013-8A2861FA-E380-4813-AB17-19A0262895E3Q47654002-69C602B6-6C50-4500-98BA-432896086C40Q51056600-14DF3630-443C-45D9-A775-26DD1885F75DQ52660928-DCD22F65-6528-427A-852C-2976BAE54AD0Q52982266-69C786F2-3104-4B66-9CC8-F9D51CAEB055Q54310284-045B3CA3-BCEF-4F0B-AEA1-2A0C14931770Q57560962-FB537C76-39A7-4796-A707-B88B235FACADQ64113455-F8CFE3AC-5D6C-47F7-9B9B-C81516ED08FBQ64241711-DD630A43-BF02-4836-B16C-648E2540D7B4Q88812861-042F6FB0-1E2D-467D-BB15-7E1DCF9165E8Q89582060-14FDF730-ABB6-49B8-AB24-202A60CF4873Q90165381-FEADAA9D-C4C1-44BC-B01D-529FBABDD3C1Q90391291-BCBF9947-BEC7-4039-A0CD-81BECAD316DDQ90474060-DC9BADBE-BB1B-4C43-A2F3-08CF1F4DD484Q90622953-45741ECD-9214-4360-8438-FE3CE8DDE723Q90626676-8F298E24-49A5-4480-B088-4C1A5BD91E66Q90833364-C43D5789-D21F-4E2B-AD35-64A96E4C0E6AQ90937340-24B01705-8F5A-4457-B101-4919A494499BQ91159266-66467688-3EE7-4BFF-B08D-8717216C2810Q91373284-85016A93-BBAF-4329-ABF5-054780AB1751Q91809931-E2A83DDD-4D13-40D7-ADC9-2CC7AFA2CE80Q91978643-AB31AF5D-637D-4B3A-A18F-BBB83EB4433EQ92026392-EC4FBA3D-80A9-443C-B201-B4E380F9150AQ92127325-D89FDF99-587D-44AB-B8A7-976955B1DE5BQ92374662-34BDB690-3B65-46D7-B4E1-17023EAE50DF
P50
description
hulumtuese
@sq
onderzoeker
@nl
researcher
@en
հետազոտող
@hy
name
Ellen Kapiteijn
@ast
Ellen Kapiteijn
@en
Ellen Kapiteijn
@es
Ellen Kapiteijn
@nl
Ellen Kapiteijn
@sl
type
label
Ellen Kapiteijn
@ast
Ellen Kapiteijn
@en
Ellen Kapiteijn
@es
Ellen Kapiteijn
@nl
Ellen Kapiteijn
@sl
prefLabel
Ellen Kapiteijn
@ast
Ellen Kapiteijn
@en
Ellen Kapiteijn
@es
Ellen Kapiteijn
@nl
Ellen Kapiteijn
@sl
P106
P21
P31
P496
0000-0002-4814-6426